Last reviewed · How we verify
Infliximab-Dyyb
Infliximab-dyyb is a TNF-alpha inhibitor monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha, blocking its pro-inflammatory signaling.
Infliximab-dyyb, marketed as Inflectra, is a TNF inhibitor used to treat various inflammatory conditions such as Crohn's disease, ulcerative colitis, and rheumatoid arthritis. It works by binding to TNFα, reducing inflammation and improving symptoms. However, it carries significant risks, including serious infections and malignancies, particularly in pediatric patients. The drug is contraindicated in patients with severe heart failure and those with a history of severe hypersensitivity reactions. Common side effects include infections, infusion-related reactions, headache, and abdominal pain.
At a glance
| Generic name | Infliximab-Dyyb |
|---|---|
| Also known as | Infliximab |
| Sponsor | Asan Medical Center |
| Drug class | TNF-alpha inhibitor; monoclonal antibody |
| Target | TNF-alpha (TNFα) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Infliximab-dyyb is a chimeric monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNF-alpha, preventing its interaction with TNF receptors on immune cells and other tissues. By neutralizing TNF-alpha, a central mediator of inflammation, the drug suppresses the inflammatory cascade underlying autoimmune and inflammatory diseases. This mechanism reduces immune cell activation, cytokine production, and tissue inflammation.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriasis
- Psoriatic arthritis
Common side effects
- Infections (including serious infections)
- Tuberculosis reactivation
- Infusion reactions
- Headache
- Abdominal pain
- Nausea
Key clinical trials
- Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial (PHASE1, PHASE2)
- Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD (NA)
- Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infliximab-Dyyb CI brief — competitive landscape report
- Infliximab-Dyyb updates RSS · CI watch RSS
- Asan Medical Center portfolio CI